Back to search

Article

Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft

2023-02-06

Abstract excerpt

Advanced cutaneous squamous cell carcinoma (cSCC) is treated with chemotherapy and/or radiotherapy, but these typically fail to achieve satisfactory clinical outcomes. There have been no preclinical studies to evaluate the effectiveness of eribulin against cSCC. Here, we examine the effects of eribulin using cSCC cell lines and a novel cSCC patient-derived xenograft (PDX) model. In the cSCC cell lines (A431 and DJ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
45e8d70f-a179-5c24-b375-d8f243137eb6
DOI
10.21203/rs.3.rs-2531053/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograftDOI 10.21203/rs.3.rs-2531053/v1
Select a neighboring publication to make it the new centre.